Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing …
Post
-
-
FDA approves Acadia’s Daybue Stix for Rett syndrome
The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and preservative-free powder formulation of trofinetide, …
-
Sobi buys Arthrosi to expand gout treatment pipeline
Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that …
-
EU inches closer to new pharma legislation amid competitiveness drive
Pharmaceutical companies marketing products in Europe could be set for a commercial boost, after legislators have agreed on a new …
-
Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
Even with Johnson & Johnson’s (J&J) $14.6bn buyout of Intra-Cellular Therapies in January setting a strong deal-making tone, 2025 still …
-
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease treatments, Qfitlia (fitusiran) and Cablivi (caplacizumab), …
-
Zealand Pharma and OTR to develop metabolic disease therapeutics
Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies …
-
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and …
-
Moderna signs deal worth up to $503m with Nanexa
Moderna has entered a licence agreement with Nanexa to add tailored release profiles to its injectable drugs. According to the contract, …
-
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments
The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to …
-
Pfizer plans job cuts in Switzerland to reduce expenses
Pfizer is set to cut jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by …
-
Boehringer’s Jascayd gains China’s NMPA approval for PPF
China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF). The …
-
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) …
-
Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML
Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025, …
-
Cell and gene therapy investment strategy pivots as funding dries up
Companies looking to push into the gene therapy (CGT) sector are navigating a more selective funding landscape amid a wider …
